BridgeBio Oncology Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2024 | $-618.0K | $-618.0K | — | $39.4K |
| Mar 2025 | $-19.6M | $-19.8M | $162.0K | $627.0K |
| Mar 2026 | $-35.9M | $-35.9M | $24.0K | $3.9M |
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2024 | $-618.0K | $-618.0K | — | $39.4K |
| Mar 2025 | $-19.6M | $-19.8M | $162.0K | $627.0K |
| Mar 2026 | $-35.9M | $-35.9M | $24.0K | $3.9M |